Safety of targeted therapies for treating immune-mediated inflammatory diseases

被引：0
|
作者：
Hoisnard, L. [1 ]
Zureik, M. [2 ]
Weill, A. [2 ]
Dray-Spira, R. [2 ]
Lebrun-Vignes, B. [3 ]
Meyer, A. [4 ]
Vegas, L. Pina [5 ]
Claudepierre, P. [5 ]
Mahevas, M. [6 ]
Michel, M. [6 ]
Cohen, J. L. [7 ]
Maury, S. [8 ]
El Karoui, K. [9 ]
Wolkenstein, P. [10 ]
Roy, L. [11 ]
Amiot, A. [12 ]
Grimbert, P. [9 ]
Sbidian, E. [10 ]
机构：
[1] Federat Hospitalo Univ True Innovat Therapy Immun, Hop Henri Mondor, Creteil, France
[2] French Natl Hlth Insurance, French Natl Agcy Med & Hlth Prod Safety, EpiPhare Sci Interest Grp Epidemiol Hlth Prod, St Denis, France
[3] Hop La Pitie Salpetriere, Serv Pharmacol, Paris, France
[4] Hop Bicetre, Serv Gastroenterol, Le Kremlin Bicetre, France
[5] Hop Henri Mondor, Serv Rhumatol, Creteil, France
[6] Hop Henri Mondor, Serv Med Interne, Creteil, France
[7] INSERM, Inst Mondor Rech Biomed, Creteil, France
[8] Hop Henri Mondor, Serv Dhematol, Creteil, France
[9] Hop Henri Mondor, Serv Nephrol & Transplantat, Creteil, France
[10] Hop Henri Mondor, Serv Dermatol, Creteil, France
[11] Hop Henri Mondor, Serv Dhematol Clin, Creteil, France
[12] Hop Henri Mondor, Serv GastroEnterol, Creteil, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2024年 / 38卷
关键词：
French National Health Data System; immune-mediated inflammatory diseases; Janus kinase inhibitors; pharmacoepidemiology; pharmacovigilance; safety;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
TH-002
引用
收藏
页码：43 / 44
页数：2
相关论文
共 50 条
  • [1] Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy
    Pereira, Rui
    Lago, Paula
    Faria, Raquel
    Torres, Tiago
    DRUG DEVELOPMENT RESEARCH, 2015, 76 (08) : 419 - 427
  • [2] Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry
    de Abreu, Paloma
    Cabrera, Sonia
    Cordovilla, Darwin
    Roman, Lourdes
    Brunengo, Cristina
    Melgarejo, Patricia
    Soto, Macarena
    Valinotti, Vannia
    Amarilla, Angelica
    Acevedo, Belem
    Pineda, Alexis
    Leiva, Evelyn
    Pusineri, Paola
    Consani, Sandra
    Zarza, Mariela
    Parodi, Clyde
    Morel, Zoilo
    Rolon, Roger
    Jara, Paola
    Aranda, Raquel
    Martinez, Laura
    Avila, Gabriela
    REUMATOLOGIA CLINICA, 2025, 21 (02):
  • [3] Chilblains in immune-mediated inflammatory diseases: a review
    Dubey, Shirish
    Joshi, Nilay
    Stevenson, Olivia
    Gordon, Caroline
    Reynolds, John A.
    RHEUMATOLOGY, 2022, 61 (12) : 4631 - 4642
  • [4] Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies
    Romero-Bogado, Liz
    Steiner, Martina
    Vasallo, Israel John Thuissard
    Andreu-Vazquez, Cristina
    Cobo-Ibanez, Tatiana
    Gomez, Alejandro Gomez
    Paredes-Romero, Maria Beatriz
    Esteban-Vazquez, Ana
    Mendez, Laura Cebrian
    De La Mano, Maria Angeles Matias
    Garcia-Yubero, Cristina
    Hernandez, Alicia Martinez
    Ortega, Mar Esteban
    Marcos, Noemi Mancenido
    Pajares, Ramon
    Alba, Concepcion Esteban
    Santos, Raquel Guillen
    Marcos, Teresa Navio
    Munoz-Fernandez, Santiago
    REVISTA CHILENA DE INFECTOLOGIA, 2023, 40 (06): : 618 - 625
  • [5] Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison
    Maier, Jeanette A.
    Castiglioni, Sara
    Petrelli, Alessandra
    Cannatelli, Rosanna
    Ferretti, Francesca
    Pellegrino, Greta
    Puttini, Piercarlo Sarzi
    Fiorina, Paolo
    Ardizzone, Sandro
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [6] Telomeres: New players in immune-mediated inflammatory diseases?
    Heba, Anne-Charlotte
    Toupance, Simon
    Arnone, Djesia
    Peyrin-Biroulet, Laurent
    Benetos, Anthanase
    Ndiaye, Ndeye Coumba
    JOURNAL OF AUTOIMMUNITY, 2021, 123
  • [7] Fibroblasts in immune-mediated inflammatory diseases: The soil of inflammation
    Zhou, Yifan
    Cao, Tianyu
    Li, Zhiguo
    Qiao, Hongjiang
    Dang, Erle
    Shao, Shuai
    Wang, Gang
    CLINICAL IMMUNOLOGY, 2024, 258
  • [8] Management of cardiovascular comorbidities in immune-mediated inflammatory diseases
    Roubille, C.
    REVUE DE MEDECINE INTERNE, 2024, 45 (04): : 194 - 199
  • [9] Management of cardiovascular comorbidities in immune-mediated inflammatory diseases
    Roubille, C.
    REVUE DE MEDECINE INTERNE, 2022, 43 : A299 - A303
  • [10] Heme cytotoxicity and the pathogenesis of immune-mediated inflammatory diseases
    Larsen, Rasmus
    Gouveia, Zelia
    Soares, Miguel P.
    Gozzelino, Raffaella
    FRONTIERS IN PHARMACOLOGY, 2012, 3
12345